Web Toolbar by Wibiya
Login | Sign Up AnonymousUser
twiter
New to Comunitee?


or Sign Up with Email

Business

>> GLAXOSMITHKLINE Latest News

AUG 29, 2014 - TheStreet

A Must Read - Share

'Fast Money' Recap: When Is the Next Market Correction?

NEW YORK (TheStreet) -- The S&P 500afell 0.17% while the iShares 20+ Year Treasury Bond ETF made new 52-week highs. On CNBC's "Fast Money" TV show, Brian Kelly, founder of Brian Kelly Capital, suggested the final stages of a bull market tend to come six to 12 months after a hike in interest rates. He likes gold near current levels.a ...

Tags: 'Fast Money' Recap: When Is the Next Market Correction?,  Glaxosmithkline Latest News

AUG 26, 2014 - Benzinga

A Must Read - Share

GSK Receives FDA Approval Of An Additional Promacta (eltrombopag) Indication For Use In Patients With Severe Aplastic Anaemia

GlaxoSmithKline plc (LSE/NYSE: GSK) announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for the once-daily use of Promacta® (eltrombopag) in patients with severe aplastic anaemia (SAA) who have had an insufficient response to immunosuppressive therapy (IST).1

Tags: GSK Receives FDA Approval Of An Additional Promacta (eltrombopag) Indication For Use In Patients With Severe Aplastic Anaemia,  Glaxosmithkline Latest News

AUG 26, 2014 - TheStreet

A Must Read - Share

4 Foreign Blue-Chip Stocks With 4% Dividend Yields to Buy

NEW YORK (TheStreet) -- What do China Petroleum & Chemical , Empresa Nacional de Electricidad , GlaxoSmithKline and Westpac Banking Corporation have in common? They are foreign, blue-chip stocks paying 4% dividends, far superior to comparableaAmerican stocks such as Exxon Mobil , Edison International , Bristol-Myers Squibb and Bank of America . Read More: 10 Stocks Carl Icahn Loves in ...

Tags: 4 Foreign Blue-Chip Stocks With 4% Dividend Yields to Buy,  Glaxosmithkline Latest News

AUG 25, 2014 - Zacks Investment Research

A Must Read - Share

AUG 25, 2014 - TheStreet

A Must Read - Share

Biotechs Rise After InterMune Acquired by Roche

NEW YORK (TheStreet) -- Shares of a number of biopharmaceutical companies are climbing after drug maker Roche agreed to buy its smaller peer, Intermunea . InterMune focuses on developing treatments for respiratory and orphan fibrotic diseases. WHAT'S NEW: Roche agreed to buy InterMune for $74 per share in an all-cash transaction, the companies announced yesterday. InterMune's stock closed at $53.80 ...

Tags: Biotechs Rise After InterMune Acquired by Roche,  Glaxosmithkline Latest News